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Abstract
Platelet-derived growth factor (PDGF) has been implicated in the pathogenesis of pulmo-
nary fibrosis. Nintedanib, a multi-kinase inhibitor that targets several tyrosine kinases,
including PDGF receptor (PDGFR), was recently approved as an anti-fibrotic agent to
reduce the deterioration of FVC in patients with idiopathic pulmonary fibrosis (IPF). How-
ever, the effects of PDGFR-α or -β on pulmonary fibrosis remain unclear. In an attempt to
clarify their effects, we herein used blocking antibodies specific for PDGFR-α (APA5) and -β
(APB5) in a bleomycin (BLM)-induced pulmonary fibrosis mouse model. The effects of
these treatments on the growth of lung fibroblasts were examined using the 3H-thymidine
incorporation assay in vitro. The anti-fibrotic effects of these antibodies were investigated
with the Ashcroft score and collagen content of lungs treated with BLM. Their effects on
inflammatory cells in the lungs were also analyzed using bronchoalveolar lavage fluid. We
investigated damage to epithelial cells and the proliferation of fibroblasts in the lungs. APA5
and APB5 inhibited the phosphorylation of PDGFR-α and -β as well as the proliferation of
lung fibroblasts induced by PDGF-AA and BB. The administration of APB5, but not APA5
effectively inhibited BLM-induced pulmonary fibrosis in mice. Apoptosis and the proliferation
of epithelial cells and fibroblasts were significantly decreased by the treatment with APB5,
but not by APA5. The late treatment with APB5 also ameliorated fibrosis in lungs treated
with BLM. These results suggest that PDGFR-α and -β exert different effects on BLM-
induced pulmonary fibrosis in mice. A specific approach using the blocking antibody for
PDGFR-βmay be useful for the treatment of pulmonary fibrosis.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a progressive and lethal fibrotic disease of the lungs [1].
The pathogenesis of IPF involves the proliferation of mesenchymal cells and collagen
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deposition after the deregulation of repair from epithelial cell damage. Since fibrogenesis is
regulated by various growth factors, targeting these molecules has potential as a strategy to
treat patients with pulmonary fibrosis [2]. Among these growth factors, platelet-derived
growth factors (PDGFs) play a major role in pulmonary fibrosis by stimulating the growth and
migration of lung fibroblasts [3,4]. Therefore, the inhibition of PDGF receptors may improve
or slow the progression of IPF.
In animal models, we and others have demonstrated that treatments with imatinib, an
inhibitor of PDGFR-α and -β, c-KIT, and Bcr-Abl, inhibited the development of pulmonary
fibrosis in radiation- and bleomycin (BLM)-induced models [5–7]. These findings suggest that
targeting the PDGF/PDGFR axis has potential in the treatment of IPF; however, clinical trials
with imatinib for patients with IPF failed to show any anti-fibrotic effects [8]. Another multiple
kinase inhibitor, nintedanib, which inhibits several receptor tyrosine kinases for PDGFs, fibro-
blast growth factors, and vascular endothelial growth factor, was found to reduce the deteriora-
tion of forced vital capacity (FVC) and acute exacerbation in patients with IPF [9]. Wollin
et al. reported that nintedanib inactivated human lung fibroblasts through the inhibition of
PDGFR-α and -β, and the IC50 of the nintedanib to inhibit the autophosphorylation of
PDGFR-α and -β was 20-50-fold less than that of imatinib [10]. The successful findings
reported for nintedanib highlight the importance of the PDGF/PDGFR axis as a therapeutic
target for IPF.
It currently remains unclear whether the selective inhibition of PDGFR is sufficient to
reduce pulmonary fibrosis by targeting a single molecule, and also if PDGFR-α or -β is a better
target for reducing fibrogenesis in the lungs. Based on phenotypic analyses of gene knockouts,
previous studies reported that PDGF isoforms and PDGFRs have different physiological func-
tions during the embryonic period [11]. Bostro¨m et al. reported that PDGF-A knockout and
partially rescued PDGFR-α null mutants displayed a lung emphysema-like phenotype due to
failed alveolar septum formation, indicating that the blockade of PDGFR-α leads to a loss of
integrity in the lungs [12]. In addition, targeted therapy with a specific antibody may reduce the
adverse events caused by multi-targeting compounds including imatinib and nintedanib [8,9].
We herein examined the effects of PDGFR-α and -β using specific blocking antibodies for
mouse PDGFR-α and -β in a BLM-induced pulmonary fibrosis mouse model.
Materials and methods
Animals and materials
Five-week-old female C57BL/6 mice were purchased from Charles River Japan, Inc. (Yoko-
hama, Japan). They were maintained in the animal facility of Tokushima University under spe-
cific pathogen-free conditions according to the guidelines of the ethics committee of our
university [6]. The present study was approved by Institutional Animal Care and Use Commit-
tee of the Tokushima University (Permission Number: 08128). The anti-mouse PDGFR block-
ing antibodies APA5 and APB5 were kindly provided by Dr. Nishikawa (Kyoto University).
MLE12 cells were purchased from the American Type Culture Collection (Manassas, VA).
Bovine serum albumin, IgG from rat serum, and PDGF-AA and PDGF-BB were purchased
from Sigma-Aldrich (St. Louis, MO). BLM was purchased from Nippon Kayaku Co. (Tokyo,
Japan).
Fibroblast isolation
Mouse lung fibroblasts were obtained according to a previously reported method [13]. The
lungs were harvested from untreated mice and minced with scissors. Minced lungs were
digested with 0.5% trypsin. Harvested cells were cultured in RPMI1640 medium supplemented
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with 10% fetal bovine serum (FBS) (GIBCO BRL, Rockville, MD) for several days. Proliferating
cells (doubling time in 10% FBS: 15 to 18 hours) were used as lung fibroblasts at five to 10 pas-
sages. These fibroblasts were positively stained with anti-vimentin and α-smooth muscle actin
antibodies, which indicate a myofibroblast phenotype, and negatively stained with an anti-
cytokeratin antibody, which indicates an epithelial cell phenotype.
Epithelial cell isolation
Lungs harvested from mice treated with or without BLM were minced with scissors [14].
Minced lungs were digested with DNase 1 (Chemicon (Merck Millipore), Darmstadt, Ger-
many), collagenase A (Roche, Basel, Switzerland), and Dispase 2 (Roche, Basel, Switzerland).
Red blood cells were removed from single cell suspensions using ACK RBC lysis buffer
(G-Biosciences, Saint Louis, MO). Thereafter, we used MACS (Miltenyi Biotec, Bergisch Glad-
bach, Germany) to isolate type 2 epithelial cells, according to the manufacturer’s instructions.
After the negative selection of leukocytes with CD45 microbeads (Miltenyi Biotec), type 2 epi-
thelial cells were positively selected using a FITC anti-mouse CD326 (Ep-CAM) antibody (Bio-
legend, San Diego, CA) and anti-FITC microbeads (Miltenyi Biotec). The purity of isolated
cells was assessed by immunocytochemistry. Cells were incubated with a 1:800 dilution of a
PE/Cy7 rat anti-mouse CD326 (Ep-CAM) antibody as the primary antibody, and an Alexa
Fluor 488 chicken anti-rat IgG antibody (Invitrogen, Eugene, OR) was used as the secondary
antibody. Nuclei were counterstained with 4’-6-diamidino-2-phenylindole (DAPI). The ratio
of Ep-CAM-positive cells was more than 60% of the selected cells.
Immunoblotting
Immunoblotting was performed for the detection of PDGFR-α and -β and phosphorylated
PDGFR-α and -β using cell lysates of mouse lung fibroblasts as described previously [6]. Cells
were cultured in 6-well plates in RPMI1640 supplemented with 0.1% FBS. After APA5 (1 μg/
ml) or APB5 (1 μg/ml) was administered, they were incubated for 1 hour and stimulated with
PDGF-AA (10 ng/ml) or PDGF-BB (10 ng/ml) for 10 minutes, respectively. Cells were lysed
with 1 ml of lysis buffer [1%NP40, 25 mM TrisHCl (pH7.4), 10 mM sodium pyrophosphate,
100 mM sodium fluoride, 10 mM EDTA, 10 mM EGTA, and 1 mM phenylmethylsulfonyl
fluoride (PMSF)]. Protein concentrations were measured by a protein assay (Bio-Rad Labora-
tories, Hercules, CA). These samples were boiled for 3 minutes and run on 7.5% SDS-PAGE.
Proteins were then blotted on Clear Blot membrane-P (Atto. Corp., Tokyo, Japan). The mem-
brane was blocked with blocking one (Nacalai Tesque, Inc., Kyoto, Japan) at RT for 1 hour
and incubated at 4˚C overnight with primary antibodies. The membrane was then incubated
with secondary antibodies at RT for 1 hour. The blot was developed using the enhanced
chemiluminescence (ECL) method (GE Healthcare, Ltd., Amersham, UK).
The first antibodies used were as follows: anti-phospho-PDGFR alpha (Tyr1018) antibody
(1:1000 dilution, #4547; Cell Signaling Technology, Inc., MA), anti-PDGFR alpha (phospho
Y754) antibody (1:1000 dilution, ab5460; Abcam, Cambridge, UK), phospho-Akt (Ser473)
antibody (1:1000 dilution, #9271; Cell Signaling Technology, Inc., MA), PDGF Receptor α
Antibody (1:1000 dilution, #3164; Cell Signaling Technology, Inc., MA), PDGF Receptor β
(28E1) Rabbit mAb (1:1000 dilution, #3169; Cell Signaling Technology, Inc., MA), AKT anti-
body (1:1000 dilution, #9272; Cell Signaling Technology, Inc., MA), and anti-β-actin antibody
(C4) (1:1000 dilution, sc-47778; Santa Cruz Biotechnology). The second antibodies used were
as follows: goat anti-rabbit IgG-HRP (1:5000 dilution, sc-2004; Santa Cruz Biotechnology) and
anti-mouse IgG-HRP (1:1000 dilution, GE Healthcare). Densitometric quantification was
done by ImageQuant LAS 4000 (GE Healthcare, Fairfield, CT).
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Proliferation assay
Lung fibroblasts were added to a 96-well plate at 8×103 cells per well. Cells (50–60% confluent)
were cultured in RPMI1640 medium supplemented with 10% FBS overnight, and then ren-
dered quiescent in RPMI1640 medium containing 0.3% FBS overnight. Cells (60–70% conflu-
ent) were then treated with PDGF-AA and BB (10 ng/ml) and various concentrations of APA5
and APB5 (0.01–1 ng/ml) for 72 hours and labeled with 3H-TdR (6.7 Ci/mmol; Amersham
Corp., Arlington Heights, IL) at 1 μCi/well for the final 18 hours. Cells were harvested on glass
filters in the cell harvester, MASHII (Labo Science Co., Tokyo, Japan), and the incorporation
of 3H-TdR was measured with a liquid scintillation counter.
Flow cytometry
Flow cytometry was performed for the detection of PDGFR-α and -β in mouse lung fibroblasts
and mouse alveolar epithelial cells. Mouse lung fibroblasts were plated onto 6-well plates
(1×105/well) and incubated in RPMI1640 medium supplemented with 10% FBS at 37˚C under
5% CO2 in humidified air. Cells (5×105) were collected and incubated for 30 minutes on ice
with PE anti-mouse CD140a (PDGFR-α) antibody, PE anti-mouse CD140b (PDGFR-β) anti-
body and purified RAT IgG (Invitrogen). Mouse alveolar epithelial cells were isolated using
MACS as described above. Cells were incubated with a FITC anti-mouse CD326 (EpCAM) anti-
body, PE anti-mouse CD140a (PDGFR-α) antibody, and PE anti-mouse CD140b (PDGFR-β)
antibody (Biolegend). Stained cells were analyzed by flow cytometry using BD LSRFortessa for
acquisition and BD FACSDiva software 6.0 (BD Biosciences, San Jose, CA) for analyses.
BLM treatment
Mice were anesthetized with pentobarbiturate, and mini-osmotic pumps (ALZET 2001, DUR-
ECT Corporation, CA) containing 200 μl saline with or without BLM (140 mg/kg) were
implanted subcutaneously into the left suprascapular lesion through an incision at the base of
the neck [15]. BLM was constantly infused with minipumps from day 0 to 7 for 7 days, as
described in the manufacturer’s protocol. Each experiment was performed on at least three
mice per group.
Administration of APA5, APB5, and IgG
APA5, APB5, and IgG from rat serum (control) were dissolved in PBS. APA5, APB5, and con-
trol rat IgG (1 mg/body) were injected intraperitoneally into each mouse every other day from
day 0 to 26. The dose and frequency of injections were selected based on previous studies
using APA5 and APB5 in mice [16,17].
Bronchoalveolar lavage
Regarding bronchoalveolar lavage (BAL), mice were anesthetized with pentobarbital and the
lungs and heart were surgically exposed. The trachea was cannulated and the lungs were
lavaged 5 times with 0.7 ml of 0.1 mM PBS. BAL cells were collected by centrifugation, and live
cells were counted using a hemocytometer. After counting the cell number in BAL fluid, cells
were cytospun onto glass slides and stained with Diff-Quik (Sysmex Co., Hyogo, Japan) for
differential cell counting.
Collagen assay
The total amount of collagen in the lungs was assessed using the Sircol Collagen Assay kit (Bio-
color Ltd., Belfast, Northern Ireland). On Day 28 after implantation of the minipumps
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containing BLM, the left lungs were harvested and homogenized in 0.5 M acetic acid (50 vol-
umes to wet lung weight) containing approximately 1 mg pepsin/10 mg tissue residue. Each
sample was incubated at room temperature for 24 hours with stirring. After centrifugation,
100 μl of each supernatant was assayed. One milliliter of Sircol dye reagent, which binds to col-
lagen, was added to each sample and then mixed for 30 minutes. After centrifugation, the pel-
lets were suspended in 1 ml of the alkali reagent included in the kit and read at 540 nm using a
spectrophotometer. Collagen standard solutions were utilized to construct a standard curve.
Histopathology
The right lungs were fixed in 10% buffered formalin and embedded in paraffin. Sections
(thickness of 3 to 4 μm) were stained with hematoxylin and eosin and then examined by light
microscopy. A numerical fibrotic scale was used (Ashcroft score) in a quantitative histological
analysis [18]. The severity of fibrotic changes in each lung section was assessed as a mean score
of severity from observed microscopic fields. Fifteen fields within each lung section were eval-
uated at a magnification of ×100. Each field was assessed individually for the severity of fibrotic
changes and given a score of 0 (normal) to 8 (total fibrosis). The mean score of all evaluated
fields was regarded as the fibrotic score. To evaluate fibrotic changes in more detail, Masson’s
trichrome staining was also performed.
Immunohistochemistry
On day 14 of the BLM treatment, harvested lungs were fixed in 10% buffered formalin
and embedded in paraffin. Lung sections (thickness of 3 to 4 μm) were deparaffinized and
rehydrated. Antigens were retrieved by heating the sections in citrate buffer. Endogenous
peroxidase activity was neutralized with 0.3% H2O2. Staining was performed using the
VECTASATIN universal quick kit (Vector Laboratories, Burlingame, CA) following the man-
ufacturer’s instructions.
To assess cell proliferation in the lungs, a rat anti-mouse Ki-67 antigen monoclonal anti-
body (Dako, Glostrup, Denmark) was used as the primary antibody. Sections were incubated
at RT for 1 hour with a 1:100 dilution of the primary antibody. After washing, they were incu-
bated with a biotinylated anti-rat secondary antibody at RT for 1 hour, followed by an incuba-
tion with ready-to-use streptavidin/peroxidase complex reagent for 10 minutes. Staining of the
sections was developed with a diaminobenzidine substrate kit (Vector Laboratories) and sec-
tions were counterstained with Mayer’s hematoxylin (MUTO PURE CHEMICALS CO., LTD.,
Tokyo, Japan). Ki-67-positive nuclei in the alveolar wall and in the interalveolar spaces of
whole sections were counted.
Regarding the detection of PDGFR expression in lung tissue sections, immunohistochemis-
try was performed as described above. As the primary antibodies, a 1:100 dilution of a rabbit
anti-PDGFR-α antibody (Cell Signaling Technology) and a 1:100 dilution of a rabbit anti-
PDGFR-β antibody (Cell Signaling Technology) were used.
Regarding the detection of apoptotic cells, sections were stained using the terminal deoxy-
nucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) method with the
DeadEnd Fluorometric TUNEL System (Promega, Madison, WI) following the manufacturer’s
instructions. Nuclei were counterstained with 4’-6-diamidino-2-phenylindole (DAPI). Fluo-
rescein-12-dUTP-labeled DNA was visualized directly by fluorescence microscopy. The num-
ber of TUNEL-positive cells per field was counted from 20 random fields at ×20.
Regarding the detection of alveolar type 2 epithelial cells, immunohistochemistry was per-
formed without antigen retrieval. As the primary antibody, a 1:2000 dilution of a rabbit anti-
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human prosurfactant protein C (proSP-C) polyclonal antibody (Chemicon (Merck Millipore))
was used. proSP-C-positive nuclei in 3 random fields were counted at ×100.
Regarding the detection of PDGFRs and pulmonary epithelial cells or mesenchymal cells,
Costainings of PDGFRs and EpCAM or α-SMA was performed. As the primary antibodies, a
rabbit anti-PDGFR-α antibody (Cell Signaling Technology) and a rabbit anti-PDGFR-β anti-
body (Cell Signaling Technology) and a FITC anti-mouse CD326(Ep-CAM) antibody (Biole-
gend) or anti-alpha smooth muscle actin antibody (abcam, Cambridge, UK) were used as the
primary antibodies. Sections were incubated overnight at 4˚C with a 1:50 dilution of the pri-
mary antibodies. After washing, they were incubated with a goat anti-rabbit IgG (H+L) cross-
adsorbed secondary antibody, Alexa Fluor 594 (Invitrogen) and donkey anti-goat IgG (H+L)
highly cross-adsorbed secondary antibody, Alexa Fluor Plus 488 (Invitrogen) at RT for 1 hour.
Nuclei were counterstained with VECTASHIELD Antifade Mounting Medium with DAPI
(Vector Laboratories). They were visualized directly by fluorescence microscopy.
Statistical analysis
Comparisons among multiple groups were performed using a one-way analysis of variance
with the Newman-Keuls post hoc correction (GraphPad Prism, version 5.0; GraphPad Soft-
ware, Inc., San Diego, CA). Differences were significant if p values were less than 0.05.
Results
APA5 and APB5 specifically inhibit the proliferation of lung fibroblasts
stimulated with PDGF-AA or -BB
We examined the expression of PDGFR-α and -β in murine lung fibroblasts using a flow cyto-
metric analysis. As shown in Fig 1A and S1A Fig, lung fibroblasts derived from C57BL/6 mice
expressed PDGFR-α and -β (positive rate; 64.5% and 81.6%, respectively). The expressions of
PDGFR-α and -β were also confirmed in another lung fibroblast cell line CCL206 (S1C Fig).
On the other hand, when we examined the alveolar epithelial cells purified from mice as
EpCAM-positive cells, the expressions of PDGFRs were not detected by flow cytometric analy-
sis even if cells were purified after bleomycin treatment (Fig 1B, S1B Fig).
Next, we examined the inhibitory effects of APA5 and APB5 on the signaling pathway of
PDGFR-α and -β (Fig 2, S2 Fig). Addition of PDGF-AA induced the phosphorylation of
PDGFR-α, but not PDGFR-β. On the other hand, PDGF-BB phosphorylated both PDGFR-α
and -β. APA5 inhibited the phosphorylation of PDGFR-α induced by both PDGF-AA and
PDGF-BB and did not blocked the phosphorylation of PDGFR-β induced by PDGF-BB. APB5
blocked the phosphorylation of PDGFR-β induced by PDGF-BB. In addition, APB5 reduced
the phosphorylation of PDGFR-α induced by PDGF-AA, although the level of inhibition was
weaker than APA5. The total inhibitory activity of PDGFR-α and -β by APA5 and APB5 was
confirmed by the phosphorylation of Akt. These results demonstrated that APA5 inhibited the
signaling of PDGFR-α, but not PDGFR-β. APB5 blocked the signaling of PDGFR-β, although
the signaling pathway of PDGFR-α was also affected by APB5.
We then examined the inhibitory effects of APA5 and APB5 on the proliferation of lung
fibroblasts using the 3H-thymidine incorporation assay (Fig 3). The treatment with APA5
inhibited the proliferation of fibroblasts induced by PDGF-AA in a dose-dependent manner,
but not that induced by PDGF-BB. APB5 showed the inhibition of the growth of lung fibro-
blasts induced by PDGF-BB, but not by PDGF-AA. These results indicated the biological spec-
ificity of APA5 or APB5 in blocking PDGFR.
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Treatment with APB5 attenuates pulmonary fibrosis in BLM-treated mice
We investigated the anti-fibrotic effects of APA5 and APB5 in the BLM-induced pulmonary
fibrosis mouse model. APA5, APB5, and control Ab were injected intraperitoneally every
Fig 1. Expression of PDGFR-α and -β by murine lung fibroblasts and lung epithelial cells. (A) A flow cytometric
analysis showed that PDGFR-α and -β were both detected on C57B/L6 lung fibroblasts. (B) Mouse alveolar type 2
epithelial cells were isolated as described in the Materials and Methods section. The cells obtained were investigated by
a FACS analysis. Neither PDGFR-α nor -β was detected in freshly isolated mouse alveolar type 2 epithelial cells. Similar
results were obtained at least two independent experiments.
https://doi.org/10.1371/journal.pone.0209786.g001
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other day from Day 0 to sacrifice on Day 28. Fibrogenesis in the lungs was evaluated by Hema-
toxylin & Eosin (Ashcroft score) and Masson’s Trichrome staining of the lungs. A histological
analysis of BLM-treated mice revealed fibrosis and collagen deposition in the subpleural areas
of the lungs. The administration of APB5 significantly decreased fibrotic changes from those
with control Ab (Fig 4A and 4B). The anti-fibrotic effects of APB5 was also confirmed by the
quantification of collagen content in the lungs (Fig 4B). However, APA5 did not attenuate pul-
monary fibrosis induced by BLM. In addition, the treatment with both APA5 and APB5 did
not enhance anti-fibrotic effects over those with APB5 alone.
Fig 2. The inhibitory effects of APA5 and APB5 on the phosphorylation of PDGFR-α -β, and Akt. Immunoblotting was performed for the detection of PDGFRs,
Akt, and their phosphorylation in lung fibroblasts. Murine lung fibroblasts were stimulated with PDGF-AA (10 ng/ml) and -BB (10 ng/ml) in the presence of the anti-
PDGF-α antibody APA5, anti-PDGFR-β antibody APB5, or control Ab. APA5 inhibited the phosphorylation of PDGFR-α induced by PDGF-AA. APB5 inhibited the
phosphorylation of PDGFR-β induced by PDGF-BB. The phosphorylation of Akt was also inhibited by both antibodies. Representative immunoblot (A) and
corresponding densitometric quantification of PDGFRs phosphorylation and Akt phosphorylation (B-D) are shown.
https://doi.org/10.1371/journal.pone.0209786.g002
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APB5, but not APA5, inhibited the proliferation of lung fibroblasts in
lungs treated with BLM
We investigated the mechanisms responsible for the stronger anti-fibrotic effects of APB5 over
those of APA5. The proliferation of mesenchymal cells mainly in fibrotic areas was analyzed
by immunohistochemistry for Ki-67. We previously confirmed in similar experiments that
most proliferating mesenchymal cells were fibroblasts [19]. As shown in Fig 5A and 5B, the
administration of APB5, but not APA5, significantly decreased the number of Ki-67-positive
proliferating cells in the inter-alveolar spaces, not alveolar wall, of lungs treated with BLM.
There were no additional effects of APA5 on the reductions observed in the number of Ki-
67-positive cells by APB5.
Fig 3. Specific inhibitory effects of APA5 and APB5 on the proliferation of lung fibroblasts. Lung fibroblasts were treated with PDGF-AA (10 ng/ml) and -BB (10
ng/ml) in the presence or absence of various concentrations of APA5 and APB5 (0.01–1 μg/ml), and then labeled with 3H-TdR at 1 μCi/well. The incorporation of
3H-TdR was measured with a liquid scintillation counter. PDGF-AA and -BB induced the proliferation of murine lung fibroblasts. APA5 inhibited the proliferation of
fibroblasts induced by PDGF-AA in a dose-dependent manner (A), but did not inhibit that induced by PDGF-BB (B). APB5 inhibited the proliferation of fibroblasts
induced by PDGF-BB in a dose-dependent manner (D), but did not inhibit that induced by PDGF-AA (C).
https://doi.org/10.1371/journal.pone.0209786.g003
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Effects of APA5 and APB5 on inflammation in lungs treated with BLM
To clarify the effects of APA5 and APB5 on inflammation in lungs treated with BLM, BAL
fluid was collected on Days 7 and 14 and analyzed. On Day 7, the numbers of all cells and neu-
trophils were higher in BLM-treated mice than in control mice. APA5 increased the number
of neutrophils, whereas APB5 decreased it. On Day 14, the numbers of all cells, macrophages,
lymphocytes, and neutrophils were higher in BLM-treated mice than in control mice. Simi-
larly, APB5 decreased the number of neutrophils. APB5 also slightly reduced the number of
lymphocytes (Table 1).
Fig 4. Treatment with APB5, but not APA5 attenuates pulmonary fibrosis in BLM-treated mice. BLM was injected subcutaneously with a mini-osmotic pump for 7
days. APA5, APB5, and IgG as a control were injected intraperitoneally every other day from the start on Day 0 to sacrifice on Day 28. (A) Representative
photomicrographs of hematoxylin & eosin and Masson’s trichrome staining of the lungs on Day 28. BLM-treated mice showed fibrosis and collagen deposition in the
subpleural areas of the lungs. The administration of APB5 attenuated fibrosis from that in BLM-treated mice. However, the administration of APA5 did not exert any
anti-fibrotic effects. Magnification ×100. (B) In the quantitative histological analysis, the severity of fibrotic changes in each lung section was assessed by the Ashcroft
score and the collagen assay on Day 28. The administration of APB5 significantly decreased the Ashcroft score and the collagen content from that in BLM-treated mice.
Data are presented as means ± SEM. N = 4 for the control and N = 4–7 for the BLM treatment groups.
https://doi.org/10.1371/journal.pone.0209786.g004
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Evaluation of epithelial injury in lungs treated with anti-PDGFR antibodies
in the BLM-induced pulmonary fibrosis model
To examine whether APA5 or APB5 affects alveolar epithelial cell injury induced by BLM, we
used the TUNEL assay to assess apoptosis in alveolar epithelial cells on Day 14. BLM-treated
mice showed a significant increase in TUNEL-positive cells in the lungs. The administration of
APA5 did not change the number of apoptotic cells from those in BLM-treated mice, whereas
that of APB5 significantly decreased their number (Fig 6A and 6B). We then assessed alveolar
type 2 epithelial cells in the lungs by immunohistochemical staining for proSP-C. The BLM
treatment caused hypertrophy and increases in the number of proSP-C-positive alveolar type 2
epithelial cells on Day 14, presumably indicating epithelial injury and regeneration. The
Fig 5. APB5, but not APA5, decreases proliferating cell numbers in inter-alveolar spaces of lungs. Mice were sacrificed on Day 14 after the administration of BLM.
The lungs were examined by immunohistochemistry. (A) Ki-67 staining is shown. The administration of APB5 resulted in a lower number of Ki-67-positive cells in the
inter-alveolar spaces than in BLM-treated mice, whereas that of APA5 did not. In the alveolar wall, there was no significant difference in the number of Ki-67-positive
cells. Magnification ×100 for alveolar wall and ×200 for inter-alveolar space. (B) Ki-67-positive nuclei in the inter-alveolar spaces and in the alveolar wall of whole
sections were counted. The treatment with APB5 reduced the number of Ki-67-positive cells in the inter-alveolar spaces significantly more than control IgG. Data are
presented as means ± SEM. N = 3 for each group.
https://doi.org/10.1371/journal.pone.0209786.g005
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administration of APA5 did not change these numbers from those in BLM-treated mice. How-
ever, the administration of APB5 significantly inhibited hypertrophy and increases in the
number of alveolar type 2 epithelial cells (Fig 7A and 7B).
Expression of PDGFR-α and -β in lungs treated with BLM
To clarify the different effects of APA5 and APB5 in vivo, we investigated the expression pat-
terns of PDGFRs in the lungs of BLM-treated mice. The staining of PDGFR-α was weakly
detected in the alveolar wall (Fig 8A). On the other hand, fibrotic areas in lungs treated with
BLM showed markedly stronger staining for PDGFR-β than for PDGFR-α possibly in mesen-
chymal cells as well as alveolar macrophages. We then examined whether PDGFR-α and -β
expressed on lung fibroblasts or epithelial cells by immunohistochemistry. We performed the
double-staining with anti-PDGFR antibody and anti-EpCAM or anti-α SMA antibody. As
shown in Fig 8B, PDGFR-α and -β were expressed on α-SMA-positive fibroblasts, not
EpCAM-positive lung epithelial cells.
Late treatment with APB5 attenuates pulmonary fibrosis in BLM-treated
mice
To examine the therapeutic anti-fibrotic activity of APB5, we injected 1 mg of APB5 every
other day from Days 15 to 27(late treatment schedule) into the BLM model. As shown in Fig 9,
APB5 significantly decreased pulmonary fibrosis and the collagen content of the lungs.
Discussion
In the present study, we examined the effects of the anti-PDGFR-α Ab APA5 and anti-
PDGFR-β Ab APB5 on the biological activities of lung fibroblasts in vitro and on BLM-
induced pulmonary fibrosis in vivo. Although the inhibitory effects of APA5 and APB5 on the
proliferation of lung fibroblasts were similar, APB5 showed a significantly higher potential
than APA5 to inhibit pulmonary fibrosis in vivo. Our results clearly indicate that the blocking
approach to PDGFR-β is superior to that to PDGFR-α for treating pulmonary fibrosis.
Table 1. Effects of APA5 and APB5 on the classification of BAL cells in mice treated with bleomycin.
Days after BLM treatment All cells (×106) Cell classification (%)
Macrophages Lymphocytes Neutrophil
Day 7
NS 0.53±0.12 91.9±9.46 3.20±0.02 2.26±0.03
BLM+IgG 1.02±0.07 75.63±5.14 4.59±0.07 10.06±0.24
BLM+APA5 1.24±0.28 67.16±10.7 7.72±0.3 21.72±1.52 ?
BLM+APB5 0.94±0.13 72.96±8.68 13.13±0.49 3.39±0.04 ��
Day 14
NS 0.43±0.15 88.0±8.69 2.12±0.01 0±0
BLM+IgG 2.12±0.4 76.6±23.8 12.6±1.04 5.27±0.17
BLM+APA5 2.44±0.14 80.7±7.81 12.7±0.81 1.94±0.02
BLM+APB5 1.93±0.28 83.3±20.7 8.36±0.35 1.41±0.03 �
Mice were treated with bleomycin (BLM) as described in the Materials and Methods section. APA5, APB5, and IgG as the control were intraperitoneally injected every
other day. Mice were sacrificed on Days 7 and 14, and BAL fluid was collected. All and differential cell counting were performed. On Day 7, APA5 significantly
increased the number of neutrophils and APB5 decreased it. On Day 14, APB5 decreased the number of neutrophils. Data are presented as means ± SEM. n = 4 for the
control and n = 5–7 for the BLM treatment group.
https://doi.org/10.1371/journal.pone.0209786.t001
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Furthermore, specific targeting to PDGFR-β may be one of the promising therapeutic
approaches for patients with pulmonary fibrosis.
Fibroblasts are involved in damaged tissue repair and fibrogenesis through PDGFR signal-
ing. They are heterogenous, expressing either PDGFR-α, -β, or both [20]. PDGFs binding to
PDGFR-α and -β promote receptor dimerization, which activate PDGFR signaling. PDGF-AA
has been reported to interact with only PDGFR-αα. On the other hand, PDGF-BB is consid-
ered to interact with PDGFR-αα, PDGFR-ββ, and PDGFR-αβ. However, a few interactions
have been demonstrated in vivo, namely, those of PDGF-AA with PDGFR-αα and PDGF-BB
with PDGFR-ββ [21]. Regarding the roles of PDGFRs in pulmonary fibrosis, there are a few
papers published. Zhou Y et al. reported the expressions of PDGFRs in murine BLM-model
[22]. They described that the level of PDGFR-α mRNA was not changed among days 4, 8 and
16 after a BLM administration. However, PDGFR-β mRNA was reported to be once decreased
Fig 6. APB5, but not APA5, decreases apoptosis in alveolar epithelial cells in lungs of BLM-treated mice. Regarding the analysis of injured epithelial cell death after
the BLM treatment on Day 14, sections were stained using the terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) method. (A)
Representative pictures of TUNEL staining are shown. Nuclei were counterstained with 4’-6-diamidino-2-phenylindole (DAPI). Magnification ×400. (B) TUNEL-
positive cells/field were counted from 6 random fields per section at ×200. BLM-treated mice showed significant increases in the number of TUNEL-positive cells in the
lungs of mice on Day 14. The administration of APA5 did not change the number of TUNEL-positive cells from that in BLM-treated mice, whereas that of APB5
significantly decreased them. Data are presented as means ± SEM. N = 2 for the control and 3 for the BLM treatment groups.
https://doi.org/10.1371/journal.pone.0209786.g006
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on day 8 and recovered on day14. On the other hand, Yoshida M et al. reported that in vivo
gene transfer of an extracellular domain of PDGFR-β ameliorated BLM-induced pulmonary
fibrosis in mice [23]. These data suggest that the roles of PDGFRs in pulmonary fibrosis are
still unclear. To our best knowledge, the present study is a first report with blocking antibodies
to analyze describing the roles of PDGFRs in pulmonary fibrosis in a mouse model.
First, we confirmed the specificity of APA5 and APB5 for PDGFRs by an immunoblotting.
The data clearly showed that APA5 inhibited the signaling pathway of PDGFR-α, not PDGFR-
β. However, APB5 affected the signaling of PDGFR-α in addition to PDGFR-β, although the
effects were weaker. The binding specificity of APA5 and APB5 for PDGFR-α and -β is dem-
onstrated in the previous papers [24, 16]. Because APA5, but not APB5, almost completely
inhibited the proliferation of fibroblasts induced by PDGF-AA, and APB5, but not APA5,
inhibited the growth induced by PDGF-BB, APA5 biologically inhibits the signaling mainly
through PDGFR-α and APB5 biologically inhibits the signaling mainly through PDGFR-β.
On the other hand, PDGFR-α expressed on fibroblasts are reported to be important for
normal tissue repair against fibrogenesis. Prasad et al. showed that PDGFR-α in fibroblasts
from normal human lungs played essential roles in epithelial repair, and fibroblasts from the
lungs of IPF patients expressed low PDGFR-α levels and exhibited deficient repair responses
[25]. Chen L et al. found the dynamic regulation of PDGFR-α expression in fibroblasts during
realveolization in the adult lungs of mice [26]. Fibroblasts expressing PDGFR-α have been
shown to localize to the alveolar entry ring [27]. In the normal murine lung, genetic fate map-
ping with the forkhead transcription factor Foxd1 transiently expressed in the mesenchymal
progenitor lineage in embryogenesis showed that resident fibroblasts (collagen-positive cells)
expressed PDGFR-α, but not PDGFR-β [20]. They were activated when epithelial cells were
denuded, and promoted the re-epithelization or accumulation of fibroblasts [28, 29]. In the
present study, the administration of APA5 promoted the infiltration of inflammatory cells,
particularly neutrophils, in BALF, but did not conclusively affect pulmonary fibrosis. We also
Fig 7. Administration of APB5, but not APA5, decreases the hyperplasia of alveolar type 2 epithelial cells induced by BLM. In the analysis of alveolar type 2
epithelial cells after the BLM treatment, sections were stained with an anti-pro SP-C antibody on Day 14. (A) Representative pictures are shown. The BLM treatment
induced hyperplasia and increased the number of SP-C-positive type 2 epithelial cells. The administration of APB5 markedly decreased the hyperplasia of type 2
epithelial cells induced by BLM. Magnification ×400. (B) ProSP-C-positive nuclei in 3 random fields were counted at ×100. The BLM treatment increased pro SP-C-
positive alveolar type 2 epithelial cells in the lungs on Day 14. The administration of APA5 did not inhibit the increase in cell counts, while that of APB5 significantly
inhibited it. Data are presented as means ± SEM. N = 3 for each group.
https://doi.org/10.1371/journal.pone.0209786.g007
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showed that the patterns of PDGFR-α and -β expression were histologically different in the lungs
of BLM-treated mice. Since murine alveolar type 2 epithelial cells in primary cultures were con-
firmed not to express PDGFR-α or -β, PDGFR-α-positive fibroblasts may exist adjacent to the
alveolar spaces of the lungs, maintain the lung structure, and serve in epithelial repair through
PDGFR-α signaling. Although the role of PDGFR-α in pulmonary fibrosis is still unclear, APA5
Fig 8. Differential expression of PDGFR-α and -β in fibrotic lungs. (A)The expression of PDGFRs in the lungs of BLM-treated mice was examined. Staining for
PDGFRs was detected in fibrotic lungs. Several cells on alveolar wall showed weak staining for PDGFR-α. PDGFR-β was not clearly detected on alveolar wall.
Mesenchymal cells clustering in fibrotic regions showed strong staining for PDGFR-α and -β; however, PDGFR-β was more strongly stained than PDGFR-α. (B) The
double-staining with anti-PDGFR antibody and anti-EpCAM or anti-α SMA antibody. PDGFR-α and -β were expressed on α-SMA-positive fibroblasts, not EpCAM-
positive lung epithelial cells.
https://doi.org/10.1371/journal.pone.0209786.g008
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may inhibit the protective function of PDGFR-α-positive resident fibroblasts in epithelial injury
and enhance inflammatory responses by blocking PDGFR-α on fibroblasts.
On the other hand, PDGFR-β in fibroblasts has been suggested to play a critical role in pul-
monary fibrosis. Previous studies demonstrated that the stimulation of PDGFR-β in fibroblasts
was essential for the proliferation and migration of fibroblasts in lung fibrogenesis. We previ-
ously reported that PDGF-BB induced the proliferation of fibroblasts more strongly than
Fig 9. Late treatment with APB5 attenuates pulmonary fibrosis in BLM-treated mice. Mice were treated with BLM as described in the Materials
and Methods section. APB5 and IgG as the control were intraperitoneally injected every other day from Day 15 to 27 (late treatment). Mice were
sacrificed on Day 28. (A) Representative pictures are shown. The late treatment with APB5 attenuated pulmonary fibrosis in BLM-treated mice. (B)
APB5 significantly decreased the Ashcroft score and the collagen content from that in BLM-treated mice. Data are presented as means ± SEM.
N = 4 for the control and N = 4–7 for the BLM treatment groups.
https://doi.org/10.1371/journal.pone.0209786.g009
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PDGF-AA [6]. In our study, the administration of APB5 markedly decreased the number of
Ki-67-positive mesenchymal cells in fibrotic lesions. Hung et al. showed that 68% of lung myo-
fibroblasts in BLM-treated mice were derived from pericytes that only expressed PDGFR-β,
indicating an elevation in the relative expression of PDGFR-β in fibrotic lungs. Pericytes were
denuded from vascular endothelial cells after the BLM treatment, which resulted in the extrav-
asation of inflammatory cells [20]. In the present study, APB5 also decreased the infiltration of
inflammatory cells, which may be related to the inhibitory effects of the activation of fibro-
blasts through the blockade of PDGFR-β.
Apart from fibroblasts, fibrocytes have been proposed as other candidates that contribute to
pulmonary fibrosis through PDGFR. The migration of bone marrow-derived fibrocytes into
damaged lungs has been reported to contribute to fibrosis. We showed that the expression of
PDGFR-β was significantly stronger in fibrocytes from IPF patients than in those from healthy
volunteers, and the migration of fibrocytes in the lungs of BLM-treated mice was inhibited
more strongly by APB5 than by APA5 [30]. APB5 may ameliorate fibrosis in the lungs of
BLM-treated mice, at least in part, by inhibiting the migration of fibrocytes.
Guzy et al. recently reported that FGF2 knockout mice showed increased mortality in
response to BLM [31]. FGF receptors expressed in mouse and human alveolar epithelial cells is
required for epithelial recovery. We also found that the blockade of pan-FGFRs with a specific
inhibitor resulted in greater injury to alveolar epithelial cells and the mortality of mice treated
with BLM (manuscript in preparation). In the present study, alveolar type 2 epithelial cells did
not express PDGFR-α or -β, and the treatment with APA5 or APB5 did not significantly affect
the mortality of mice. These results suggest that in contrast to FGFR, the blockade of PDGFRs
is not harmful for alveolar epithelial cells.
Furthermore, in our experiments, the administration of APB5 during the late fibrotic phase
also effectively ameliorated pulmonary fibrosis. In the model of BLM-induced pulmonary
fibrosis, the early phase (Days 1–14) represents inflammation and the impaired repair of epi-
thelial cell injury, while the late phase (Days 15–28) represents the accumulation of fibroblasts
and collagen deposition. The effectiveness of the late administration of APB5 implies that
APB5 did not only improve acute injury, but also inhibited chronic fibrosis, indicating the
therapeutic anti-fibrotic effects of the anti-PDGFR-β antibody.
In summary, PDGFR-α and -β exerted different effects on BLM-induced pulmonary fibrosis
in mice. In fibrotic lungs, PDGFR-β-dependent pathways appear to more strongly contribute to
the progression of pulmonary fibrosis than those of PDGFR-α, and the specific inhibition of
PDGFR-β, but not PDGFR-α effectively inhibits pulmonary fibrosis. Therefore, the anti-PDGFR-
β antibody may be a useful therapeutic modality without lung toxicity for patients with IPF.
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